• 1
    von Willebrand E. Hereditary pseudohemofil. Finska Lakarsallskapets Handl 1926; 67: 7112.
  • 2
    Kadir RA. Women and inherited bleeding disorders. Haemophilia 2011; 17(Suppl 1): 12.
  • 3
    Kouides PA. Females with von Willebrand disease: 72 years as the silent majority. Haemophilia 1998; 4: 66576.
  • 4
    Byams VR, Anderson BL, Grant AM, Atrash H, Schulkin J. Evaluation of bleeding disorders in women with menorrhagia: a survey of obstetrician-gynecologists. Am J Obstet Gynecol 2012; 207: 269e1-5.
  • 5
    Dilley A, Drews C, Lally C, Austin H, Barnhart E, Evatt B. A survey of gynecologists concerning menorrhagia: perceptions of bleeding disorders as a possible cause. J Womens Health Gend Based Med 2002; 11: 3944.
  • 6
    Kadir RA, Sabin CA, Pollard D, Lee CA, Economides DL. Quality of life during menstruation in patients with inherited bleeding disorders. Haemophilia 1998; 4: 83641.
  • 7
    Lee CA, Chi C, Pavord SR, Bolton-Maggs PH, Pollard D, Hinchcliffe-Wood A, Kadir RA. The obstetric and gynaecological management of women with inherited bleeding disorders–review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization. Haemophilia 2006; 12: 30136.
  • 8
    Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351: 4859.
  • 9
    Edlund M, Blomback M, von Schoultz B, Andersson O. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996; 53: 2348.
  • 10
    Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. von Willebrand disease in women with menorrhagia: a systematic review. BJOG 2004; 111: 73440.
  • 11
    Philipp CS, Dilley A, Miller CH, Evatt B, Baranwal A, Schwartz R, Bachmann G, Saidi P. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003; 1: 47784.
  • 12
    Bevan JA, Maloney KW, Hillery CA, Gill JC, Montgomery RR, Scott JP. Bleeding disorders: a common cause of menorrhagia in adolescents. J Pediatr 2001; 138: 85661.
  • 13
    Miller CH, Philipp CS, Stein SF, Kouides PA, Lukes AS, Heit JA, Byams VR, Dowling NF, Kulkarni R. The spectrum of haemostatic characteristics of women with unexplained menorrhagia. Haemophilia 2011; 17: e2239.
  • 14
    Lumsden MA, Belli AM, Crowe D, Gunaratnam Y, Gray S, McPherson K, Parkin D, Preston J, Shapley M, York B. CG44 Heavy menstrual bleeding: full guideline. London: RCOG Press, 2007.
  • 15
    Committee on Practice Bulletins-Gynecology. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol 2012; 120: 197206.
  • 16
    Tosetto A, Castaman G, Rodeghiero F. Bleeding scores in inherited bleeding disorders: clinical or research tools? Haemophilia 2008; 14: 41522.
  • 17
    Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, Neunert C, Lillicrap D. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8: 20635.
  • 18
    Tosetto A, Castaman G, Plug I, Rodeghiero F, Eikenboom J. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost 2011; 9: 11438.
  • 19
    Kirtava A, Drews C, Lally C, Dilley A, Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia 2003; 9: 2927.
  • 20
    Lockwood CJ. Mechanisms of normal and abnormal endometrial bleeding. Menopause 2011; 18: 40811.
  • 21
    Agarwal U, El Sheikh S, Kulkarni A, Baff D, Kadir RA. von Willebrand factor expression in endometrial endothelial cells in women with menorrhagia. Fertil Steril 2010; 94: 23357.
  • 22
    James AH. Diagnosis and management of women with bleeding disorders–international guidelines and consensus from an international expert panel. Haemophilia 2011; 17(Suppl 1): 35.
  • 23
    Kadir RA. Gynecology. In: Lee CA, Kadir RA, Kouides PA, eds. Inherited Bleeding Disorders in Women. Chichester: Blackwell Publishing Inc, 2009: 7089.
  • 24
    Davies J, Kadir RA. Endometrial haemostasis and menstruation. Rev Endocr Metab Disord 2012; 13: 28999.
  • 25
    Balak DM, Gouw SC, Plug I, Mauser-Bunschoten EP, Vriends AH, van Diemen-Homan JE, Rosendaal FR, van der Bom JG. Prenatal diagnosis for haemophilia: a nationwide survey among female carriers in the Netherlands. Haemophilia 2012; 18: 58492.
  • 26
    Peyvandi F. Carrier detection and prenatal diagnosis of hemophilia in developing countries. Semin Thromb Hemost 2005; 31: 54454.
  • 27
    Chi C. Antenatal diagnosis. In: Lee CA, Kadir RA, Kouides PA, eds. Inherited Bleeding Disorders in Women. Chichester: Blackwell Publishing Ltd, 2009: 99123.
  • 28
    Chi C, Hyett JA, Finning KM, Lee CA, Kadir RA. Non-invasive first trimester determination of fetal gender: a new approach for prenatal diagnosis of haemophilia. BJOG 2006; 113: 23942.
  • 29
    Devaney SA, Palomaki GE, Scott JA, Bianchi DW. Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. JAMA 2011; 306: 62736.
  • 30
    Lo YM. Prenatal diagnosis: progress through plasma nucleic acids. Nat Rev Genet 2007; 8: 717.
  • 31
    Tsui NB, Kadir RA, Chan KC, Chi C, Mellars G, Tuddenham EG, Leung TY, Lau TK, Chiu RW, Lo YM. Noninvasive prenatal diagnosis of hemophilia by microfluidics digital PCR analysis of maternal plasma DNA. Blood 2011; 117: 368491.
  • 32
    Birch L, English CA, O'Donoghue K, Barigye O, Fisk NM, Keer JT. Accurate and robust quantification of circulating fetal and total DNA in maternal plasma from 5 to 41 weeks of gestation. Clin Chem 2005; 51: 31220.
  • 33
    Tuddenham EG. Genetic and laboratory diagnosis. In: Lee CA, Kadir RA, Kouides PA, eds. Inherited Bleeding Disorders in Women. Chichester: Blackwell Publishing Ltd, 2009: 908.
  • 34
    Handyside AH, Pattinson JK, Penketh RJ, Delhanty JD, Winston RM, Tuddenham EG. Biopsy of human preimplantation embryos and sexing by DNA amplification. Lancet 1989; 1: 3479.
  • 35
    Lee CA, Kadir RA, Kouides PA, Edlund M, Tuddenham EG. Inherited Bleeding Disorders in Women. Chichester: Blackwell Publishing Ltd, 2009.
  • 36
    Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B. Prevalence and risk factors of severe obstetric haemorrhage. BJOG 2008; 115: 126572.
  • 37
    James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia 2005; 11: 295307.
  • 38
    James AH, Jamison MG. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost 2007; 5: 11659.
  • 39
    Shahbazi S, Moghaddam-Banaem L, Ekhtesari F, Ala FA. Impact of inherited bleeding disorders on pregnancy and postpartum hemorrhage. Blood Coagul Fibrinolysis 2012; 23: 6037.
  • 40
    Chauleur C, Cochery-Nouvellon E, Mercier E, Aya G, Fabbro-Peray P, Mismetti P, Lissade-Lavigne G, Gris JC. Some hemostasis variables at the end of the population distributions are risk factors for severe postpartum hemorrhages. J Thromb Haemost 2008; 6: 206774.
  • 41
    Huq FY, Kadir RA. Management of pregnancy, labour and delivery in women with inherited bleeding disorders. Haemophilia 2011; 17(Suppl 1): 2030.
  • 42
    McLintock C, James AH. Obstetric hemorrhage. J Thromb Haemost 2011; 9: 144151.
  • 43
    Stinger HK, Spinella PC, Perkins JG, Grathwohl KW, Salinas J, Martini WZ, Hess JR, Dubick MA, Simon CD, Beekley AC, Wolf SE, Wade CE, Holcomb JB. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 2008; 64: S7985; discussion.
  • 44
    de Lange NM, Lance MD, de Groot R, Beckers EA, Henskens YM, Scheepers HC. Obstetric hemorrhage and coagulation: an update. Thromboelastography, thromboelastometry, and conventional coagulation tests in the diagnosis and prediction of postpartum hemorrhage. Obstet Gynecol Surv 2012; 67: 42635.
  • 45
    Thornton P, Douglas J. Coagulation in pregnancy. Best Pract Res Clin Obstet Gynaecol 2010; 24: 33952.
  • 46
    Solomon C, Collis RE, Collins PW. Haemostatic monitoring during postpartum haemorrhage and implications for management. Br J Anaesth 2012; 109: 85163.
  • 47
    de Lloyd L, Bovington R, Kaye A, Collis RE, Rayment R, Sanders J, Rees A, Collins PW. Standard haemostatic tests following major obstetric haemorrhage. Int J Obstet Anesth 2011; 20: 13541.
  • 48
    Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012; 114: 26174.
  • 49
    Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, Sibony O, Mahieu-Caputo D, Hurtaud-Roux MF, Huisse MG, Denninger MH, de Prost D. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5: 26673.
  • 50
    Arulkumaran S, Mavrides E, Penney GC. Prevention and management of postpartum haemorrhage. RCOG Green-top Guideline 52. 2009.
  • 51
    Girdauskas E, Kempfert J, Kuntze T, Borger MA, Enders J, Fassl J, Falk V, Mohr FW. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. J Thorac Cardiovasc Surg 2010; 140: 111724.
  • 52
    Gorlinger K. Coagulation management during liver transplantation. Hamostaseologie 2006; 26: S6476.
  • 53
    Johansson PI, Stissing T, Bochsen L, Ostrowski SR. Thrombelastography and tromboelastometry in assessing coagulopathy in trauma. Scand J Trauma Resusc Emerg Med 2009; 17: 45.
  • 54
    Huissoud C, Carrabin N, Audibert F, Levrat A, Massignon D, Berland M, Rudigoz RC. Bedside assessment of fibrinogen level in postpartum haemorrhage by thrombelastometry. BJOG 2009; 116: 1097102.
  • 55
    Borgman MA, Spinella PC, Perkins JG, Grathwohl KW, Repine T, Beekley AC, Sebesta J, Jenkins D, Wade CE, Holcomb JB. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007; 63: 80513.
  • 56
    Rajasekhar A, Gowing R, Zarychanski R, Arnold DM, Lim W, Crowther MA, Lottenberg R. Survival of trauma patients after massive red blood cell transfusion using a high or low red blood cell to plasma transfusion ratio. Crit Care Med 2011; 39: 150713.
  • 57
    Simon L, Santi TM, Sacquin P, Hamza J. Pre-anaesthetic assessment of coagulation abnormalities in obstetric patients: usefulness, timing and clinical implications. Br J Anaesth 1997; 78: 67883.
  • 58
    Fenger-Eriksen C, Jensen TM, Kristensen BS, Jensen KM, Tonnesen E, Ingerslev J, Sorensen B. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost 2009; 7: 795802.
  • 59
    Rahe-Meyer N, Solomon C, Winterhalter M, Piepenbrock S, Tanaka K, Haverich A, Pichlmaier M. Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery. J Thorac Cardiovasc Surg 2009; 138: 694702.
  • 60
    Schochl H, Posch A, Hanke A, Voelckel W, Solomon C. High-dose fibrinogen concentrate for haemostatic therapy of a major trauma patient with recent clopidogrel and aspirin intake. Scand J Clin Lab Invest 2010; 70: 4537.
  • 61
    Bell SF, Rayment R, Collins PW, Collis RE. The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. Int J Obstet Anesth 2010; 19: 21823.
  • 62
    Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007; 92: 8469.
  • 63
    Sheppard BL, Bonnar J. Fibrinolysis in decidual spiral arteries in late pregnancy. Thromb Haemost 1978; 39: 7518.
  • 64
    Svanberg L, Astedt B, Nilsson IM. Abruptio placentae–treatment with the fibrinolytic inhibitor tranexamic acid. Acta Obstet Gynecol Scand 1980; 59: 12730.
  • 65
    Peitsidis P, Kadir RA. Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opin Pharmacother 2011; 12: 50316.
  • 66
    Ducloy-Bouthors AS, Jude B, Duhamel A, Broisin F, Huissoud C, Keita-Meyer H, Mandelbrot L, Tillouche N, Fontaine S, Le Goueff F, Depret-Mosser S, Vallet B, Susen S. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care 2011; 15: R117.
  • 67
    Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 58692.
  • 68
    Shakur H, Elbourne D, Gulmezoglu M, Alfirevic Z, Ronsmans C, Allen E, Roberts I. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials 2010; 11: 40.
  • 69
    Moscardo F, Perez F, de la Rubia J, Balerdi B, Lorenzo JI, Senent ML, Aznar I, Carceller S, Sanz MA. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 2001; 114: 1746.
  • 70
    Phillips LE, McLintock C, Pollock W, Gatt S, Popham P, Jankelowitz G, Ogle R, Cameron PA. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. Anesth Analg 2009; 109: 190815.
  • 71
    Phillips LE, Zatta AJ, Schembri NL, Noone AK, Isbister J. Uncontrolled bleeding in surgical patients: the role of recombinant activated factor VIIa. Curr Drug Targets 2009; 10: 74470.
  • 72
    Alfirevic Z, Elbourne D, Pavord S, Bolte A, van Geijn H, Mercier F, Ahonen J, Bremme K, Bodker B, Magnusdottir EM, Salvesen K, Prendiville W, Truesdale A, Clemens F, Piercy D, Gyte G. Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000–2004. Obstet Gynecol 2007; 110: 12708.
  • 73
    Welsh A, McLintock C, Gatt S, Somerset D, Popham P, Ogle R. Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage. Aust N Z J Obstet Gynaecol 2008; 48: 126.
  • 74
    Ahonen J. The role of recombinant activated factor VII in obstetric hemorrhage. Curr Opin Anaesthesiol 2012; 25: 30914.